1. Home
  2. VOYA vs IMVT Comparison

VOYA vs IMVT Comparison

Compare VOYA & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Voya Financial Inc.

VOYA

Voya Financial Inc.

HOLD

Current Price

$95.88

Market Cap

8.6B

Sector

Finance

ML Signal

HOLD

Logo Immunovant Inc.

IMVT

Immunovant Inc.

HOLD

Current Price

$28.54

Market Cap

8.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VOYA
IMVT
Founded
1975
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Life Insurance
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.6B
8.5B
IPO Year
2012
2019

Fundamental Metrics

Financial Performance
Metric
VOYA
IMVT
Price
$95.88
$28.54
Analyst Decision
Buy
Buy
Analyst Count
12
17
Target Price
★ $107.83
$48.88
AVG Volume (30 Days)
840.6K
★ 1.4M
Earning Date
11-02-2026
11-09-2026
Dividend Yield
★ 1.91%
N/A
EPS Growth
★ 1.94
N/A
EPS
★ 2.73
N/A
Revenue
★ $8,189,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.47
N/A
P/E Ratio
$36.04
★ N/A
Revenue Growth
★ 1.73
N/A
52 Week Low
$64.50
$19.21
52 Week High
$105.64
$45.42

Technical Indicators

Market Signals
Indicator
VOYA
IMVT
Relative Strength Index (RSI) 46.61 32.15
Support Level $92.30 $25.83
Resistance Level $104.18 $29.83
Average True Range (ATR) 2.04 1.24
MACD 0.30 0.16
Stochastic Oscillator 44.29 31.44

Price Performance

Historical Comparison
VOYA
IMVT

About VOYA Voya Financial Inc.

Voya Financial Inc is a financial services company, which, through its subsidiaries, provides various investment, insurance, and retirement solutions to individual and institutional clients in the United States. Its products and services include tax savings plans, individual retirement accounts, group life insurance plans, and employee benefits products, among others. The company tailors each of its products to the needs of its customer base. It operates its business through three principal lines: Retirement, Investment Management and Employee Benefits.The majority revenue is from Retirement segment.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.

Share on Social Networks: